Low v. Omni Life Science Inc

District Court, W.D. Oklahoma·Decided July 17, 2019·No. 5:18-cv-00305·Unknown

Opinion

IN THE UNTIED STATES DISTRICT COURT FOR THE WESTERN DISTRICT OF OKLAHOMA

WARREN G. LOW and ) THOMAS K. TKACH, ) ) Plaintiffs, ) ) v. ) Case No. CIV-18-305-SLP ) OMNI LIFE SCIENCE, INC. ) GEORGE CIPOLLETTI, ) ELIZABETH CIPOLLETTI, and ) JOHN DOES 1-10, ) ) Defendants. )

O R D E R

Before the Court is the Motion to Dismiss Counts II, III, and IV of Plaintiffs’ Amended Complaint [Doc. No. 14] filed by Defendants OMNI Life Science, Inc., George Cipolletti, and Elizabeth Cipolletti. It is at issue. See Resp., Doc No. 19; Reply, Doc. No. 22. These named defendants seek dismissal of Plaintiffs’ second, third, and fourth causes of action—for fraud, negligent misrepresentation, and negligence performance of contract, respectively—based on Federal Rules of Civil Procedure 8(a), 9(b), and 12(b)(6).1 Mr. Cipolletti and Ms. Cipolletti also seek dismissal of all claims asserted against them based on the fiduciary shield doctrine under Rule 12(b)(6) and based on the Court’s lack of personal jurisdiction over them under Rule 12(b)(2). Finally, Defendants assert that the

1 It is unclear from Plaintiffs’ Amended Complaint whether the negligent performance of contract claim is asserted against OMNI only, or also against Mr. Cipolletti and Ms. Cipolletti as well. See Am. Compl. ¶¶ 84-89, Doc. No. 9 (referencing “Defendants”). Because the Court is dismissing the negligent breach of contract claim regardless of which defendants it is asserted against, the Court need not resolve this question. claims asserted against the John Doe defendants—who are “officers, directors or shareholders of OMNI”—should be dismissed as improperly brought. Am. Compl. ¶ 6, Doc. No. 9. Defendants do not seek dismissal of Plaintiffs’ breach of contract claim (the

first count in the Amended Complaint), which is asserted against OMNI only. Plaintiffs invoke the Court’s subject-matter jurisdiction under 28 U.S.C. § 1332(a). I. Background2

Plaintiffs are medical doctors who entered into a product development and clinical surgical consulting service agreement with OMNI. Pursuant to that agreement, Plaintiffs were to provide consulting services to OMNI related to knee and hip reconstruction and replacement products in exchange for certain percentages of OMNI’s net sales of such products. These royalty payments were to be made at least annually, and within 60 days after OMNI’s annual calculation of its net sales, subject to market-caused barriers to payment that might arise, with such payment timing changes to be reasonably consented

to by Plaintiffs. The gravamen of Plaintiffs’ lawsuit is that the payments were not made or, when made, were not made timely. Plaintiffs also claim they were misled by Defendants about calculation of these payments and when they would be paid. From February 2010 through July 2017, OMNI—via various officers or employees—sent at least 28 communications to Plaintiffs regarding calculation of the

amounts owed by OMNI to Plaintiffs and when such payments would be made. Ten of

2 The factual summary herein is taken from Plaintiffs’ Amended Complaint [Doc. No. 9] and accepted as true for purposes of deciding Defendants’ motion. See Ashcroft v. Iqbal, 556 U.S. 662, 678 (2009). these communications came from Mr. Cipolletti and five came from Ms. Cipolletti. The remainder were sent by other OMNI officers or employees not named as defendants in this action. In its communications regarding the royalty payments, OMNI (per Plaintiffs)

“improperly and deceitfully calculat[ed Plaintiffs’] Royalties . . . by improperly deducting the average cost of goods sold, sales management compensation and related expenses, medical device taxes and shipping revenues from the amount used to calculate [Plaintiffs’] royalties” and by “improperly exclud[ing] amounts invoiced to and collected from the Products used by surgeons at St. Anthony’s Bone and Joint Hospital” and “amounts

invoiced for and collected from the Apex Posterior Stabilized Knee System,” “the Apex Revision Knee System,” “the Apex Revision Tibia,” “the Apex Modular Tibia,” and for “the license OMNI sold to its affiliate . . . to manufacture, distribute and sell as many of the Products as [the affiliate] wishe[d] in multiple countries.” Id. ¶¶ 26, 29-35. Plaintiffs also assert that Defendants misrepresented to them when royalty payments would be made

in these communications. Mr. Cipolletti and Ms. Cipolletti are two of OMNI’s officers and are residents of Massachusetts and Pennsylvania, respectively.3 Plaintiffs allege Mr. Cipolletti “made

3 Mr. Cipolletti’s role with OMNI is unclear. In different portions of their Amended Complaint [Doc. No. 9], Plaintiffs describe him as “OMNI’s Chief Technology Officer” (¶ 4), “OMNI’s President and Chief executive Officer” (¶ 45), “OMNI’s Chief Executive Officer” (¶ 53), “OMNI’s President and Chief Technology Officer” (¶ 61), and “OMNI’s Founder and Chief Technology Officer” (¶ 64). Plaintiffs also reference Rick Randall as being “OMNI’s CEO,” as opposed to that position being occupied by Mr. Cipolletti. Id. ¶ 66. Ms. Cipolletti is “OMNI’s General Counsel and Compliance Officer.” Id. ¶ 5. Defendants indicate that Mr. Cipolletti is OMNI’s chief technology officer and that Ms. Cipolletti is its general counsel. See Mot. 1, Doc. No. 14. The specific officer position(s) occupied by Mr. Cipolletti is not determinative for the issues addressed herein. several trips to Oklahoma in connection with the Product Development and Clinical Surgical Consulting Services Agreement Plaintiffs entered into with . . . OMNI” and also made multiple false promises to Plaintiffs regarding when royalty payments would be

made. Id. ¶ 4. Mr. Cipolletti sent Plaintiffs multiple communications relating to royalties owed by OMNI to Plaintiffs which Plaintiffs allege to have been intentionally misleading. Plaintiffs allege that Ms. Cipolletti “sent [them] numerous false ‘Statements of Account’ in connection with the Product Development and Clinical Surgical Consulting Agreement Plaintiffs entered into with . . . OMNI” and “also sent letters to Plaintiffs . . . in

Oklahoma[] which . . . contained false and deceptive statements”—presumably the five specific communications referenced supra. Id. ¶ 5. II. Pleading standard

In considering a motion to dismiss pursuant to Rule 12(b)(6), a court must determine whether the plaintiff has stated claims upon which relief may be granted. Under Rule 8(a)(2), a pleading is to contain “a short and plain statement of [each] claim showing that the pleader is entitled to relief.” While Rule 8(a)(2) “does not require ‘detailed factual allegations,’ . . . it demands more than an unadorned, the-defendant-unlawfully-harmed- me accusation.” Iqbal, 556 U.S. at 678 (quoting Bell Atl. Corp. v. Twombly, 550 U.S. 544, 555 (2007)). As such, “labels and conclusions” and “a formulaic recitation of the elements

of a cause of action” are insufficient. Twombly, 550 U.S. at 555. In essence, a plaintiff must “nudge[] [his] claims across the line from conceivable to plausible” in order to survive a motion for dismissal. Id. at 570. To assess the sufficiency of claims made by a plaintiff, a two-pronged approach is deployed. First, “a judge ruling on a defendant’s motion to dismiss a complaint must accept as true all of the factual allegations contained in the complaint.” Twombly, 550 U.S. at 572

(quotation marks and citation omitted). A court need not, however, accept the veracity of “mere conclusory statements.” Iqbal, 556 U.S. at 678.

Free access — add to your briefcase to read the full text and ask questions with AI

Low v. Omni Life Science Inc, (W.D. Okla. 2019).

Low v. Omni Life Science Inc (Low v. Omni Life Science Inc) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

Calder v. Jones
465 U.S. 783 (Supreme Court, 1984)
Burger King Corp. v. Rudzewicz
471 U.S. 462 (Supreme Court, 1985)
Bell Atlantic Corp. v. Twombly
550 U.S. 544 (Supreme Court, 2007)
Ashcroft v. Iqbal
556 U.S. 662 (Supreme Court, 2009)
Koch v. Koch Industries, Inc.
203 F.3d 1202 (Tenth Circuit, 2000)
Finstuen v. Crutcher
496 F.3d 1139 (Tenth Circuit, 2007)
Dudnikov v. Chalk & Vermilion Fine Arts, Inc.
514 F.3d 1063 (Tenth Circuit, 2008)
Union Standard Insurance v. Hobbs Rental Corp.
566 F.3d 950 (Tenth Circuit, 2009)
United States v. Wayne
591 F.3d 1326 (Tenth Circuit, 2010)
Khalik v. United Air Lines
671 F.3d 1188 (Tenth Circuit, 2012)
Newsome v. Gallacher
722 F.3d 1257 (Tenth Circuit, 2013)
Erlich v. Menezes
981 P.2d 978 (California Supreme Court, 1999)
Ottis v. FISCHER PRICE
627 F. Supp. 2d 1040 (D. Nebraska, 2008)
Lillard v. Stockton
267 F. Supp. 2d 1081 (N.D. Oklahoma, 2003)
Bowman v. Presley
2009 OK 48 (Supreme Court of Oklahoma, 2009)
Robinson Helicopter Co., Inc. v. Dana Corp.
102 P.3d 268 (California Supreme Court, 2004)
Daimler AG v. Bauman
134 S. Ct. 746 (Supreme Court, 2014)
Walden v. Fiore
134 S. Ct. 1115 (Supreme Court, 2014)
Wenz v. Memery Crystal
55 F.3d 1503 (Tenth Circuit, 1995)